1. Home
  2. NMCO vs MLYS Comparison

NMCO vs MLYS Comparison

Compare NMCO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal Credit Opportunities Fund

NMCO

Nuveen Municipal Credit Opportunities Fund

HOLD

Current Price

$10.39

Market Cap

560.1M

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$35.24

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMCO
MLYS
Founded
2019
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
560.1M
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
NMCO
MLYS
Price
$10.39
$35.24
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$47.33
AVG Volume (30 Days)
207.6K
1.5M
Earning Date
01-01-0001
02-11-2026
Dividend Yield
5.43%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.52
$8.24
52 Week High
$11.64
$47.65

Technical Indicators

Market Signals
Indicator
NMCO
MLYS
Relative Strength Index (RSI) 47.89 36.49
Support Level $10.17 $34.21
Resistance Level $10.36 $36.61
Average True Range (ATR) 0.10 1.49
MACD 0.02 -0.02
Stochastic Oscillator 84.48 24.58

Price Performance

Historical Comparison
NMCO
MLYS

About NMCO Nuveen Municipal Credit Opportunities Fund

Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: